Skip to NavigationSkip to content

Pfizer's Lyrica achieves endpoint as adjunct in paediatric epilepsy

Published on 18/05/18 at 10:19am

Pfizer has revealed new Phase 3 data for its oral epilepsy therapy Lyrica (pregbalin) as an adjunctive treatment for partial onset seizures associated with the condition in paediatric patients aged from one month to less than four years, demonstrating that higher dose of the drug met its primary endpoint in the study.  

The FDA-mandated post-marketing study examined the use of Lyrica in 175 paediatric patients with partial onset seizures who were not adequately controlled with one to three concomitant antiepileptic drugs from across 52 centres in 22 countries. It was found that the upper dose of 14mg showed a statistically significant reduction in seizure frequency in patients compared to placebo.

However, the lower dose used in the trial, at 7mg, failed to demonstrate the same statistical significance.

The safety profile for the drug was said to be consistent with previous studies, with the most common adverse reactions being somnolence, upper respiratory tract infection and pneumonia.

“The Phase 3 top-line results reinforce the efficacy and safety profile of Lyrica for paediatric epilepsy patients,” said Dr James M. Rusnak, Chief Development Officer, Internal Medicine, at Pfizer. “These findings add to the data available for LYRICA in the paediatric patient population for a complex and difficult-to-treat condition.”

Lyrica is currently approved for the treatment of epilepsy, but only in patients aged four and over.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches